Developing DAS181 for influenza and other infections

Taking a unique approach by targeting the virus host cell, Ansun BioPharma of San Diego, California is developing lead candidate Fludase (DAS181), which has shown potential for the treatment of parainfluenza, influenza and other viruses, including resistant strains.

Like Comment
Page of
Go to the profile of Ansun Biopharma

Ansun Biopharma

Ansun BioPharma is a clinical stage biopharmaceutical company located in San Diego, California. Ansun is focused on the development of unique host-directed anti-viral therapies to treat hospitalized patients infected with life-threatening respiratory viruses.

No comments yet.